A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

March 20, 2026 updated by: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH2929 Injection in Patients With Acute Exacerbations of Generalized Pustular Psoriasis

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo. The aim was to demonstrate the efficacy and safety of TQH2929 injection in patients with acute exacerbations of generalized pustular psoriasis, with a total of 36 subjects.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

36

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100191
        • Not yet recruiting
        • Peking University Third Hospital
        • Contact:
      • Beijing, Beijing Municipality, China, 100034
        • Recruiting
        • Peking University First Hospita
        • Contact:
    • Fujian
      • Fuzhou, Fujian, China, 350000
        • Not yet recruiting
        • The First Affiliated Hospital Of Fujian Medical University
        • Contact:
    • Guangdong
      • Guangzhou, Guangdong, China, 510120
        • Not yet recruiting
        • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
        • Contact:
      • Guangzhou, Guangdong, China, 510091
        • Not yet recruiting
        • Southern Medical University Dermatology Hospital
        • Contact:
    • Guizhou
      • Guiyang, Guizhou, China, 550004
        • Not yet recruiting
        • The Affiliated Hospital of Guizhou Medical University
        • Contact:
    • Hebei
      • Shijiazhuang, Hebei, China, 050000
        • Not yet recruiting
        • The Second Hospital of Hebei Medical University
        • Contact:
    • Henan
      • Luoyang, Henan, China, 471000
        • Not yet recruiting
        • The Second Affiliated Hospital of Henan University of Science and Technology
        • Contact:
      • Zhengzhou, Henan, China, 450003
        • Not yet recruiting
        • Henan Provincial People's Hospital
        • Contact:
      • Zhengzhou, Henan, China, 450000
        • Not yet recruiting
        • Zhengzhou Central Hospital
        • Contact:
      • Zhengzhou, Henan, China, 450052
        • Not yet recruiting
        • The Fifth Affiliated Hospital of Zhengzhou University
        • Contact:
    • Hubei
      • Shiyan, Hubei, China, 442000
        • Not yet recruiting
        • Shiyan Renmin Hospital
        • Contact:
      • Wuhan, Hubei, China, 430060
        • Not yet recruiting
        • Renmin Hospital of Wuhan University
        • Contact:
    • Hunan
      • Changsha, Hunan, China, 410008
        • Not yet recruiting
        • Xiangya Hospital of Central South University
        • Contact:
      • Changsha, Hunan, China, 410007
        • Not yet recruiting
        • The First Hospital of Hunan University of Chinese Medicine
        • Contact:
      • Huaihua, Hunan, China, 41800
        • Not yet recruiting
        • The General Hospital Of Hunan University Of Medicine
        • Contact:
    • Jilin
      • Changchun, Jilin, China, 130012
        • Not yet recruiting
        • The First Hospital of Jilin University
        • Contact:
    • Liaoning
      • Shenyang, Liaoning, China, 110001
        • Not yet recruiting
        • The First Hospital of China Medical University
        • Contact:
    • Shandong
      • Jinan, Shandong, China, 250022
        • Not yet recruiting
        • Shandong First Medical University Affiliated Dermatology Hospital
        • Contact:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200443
        • Not yet recruiting
        • Shanghai skin disease hospital
        • Contact:
    • Shanxi
      • Xi’an, Shanxi, China, 710061
        • Not yet recruiting
        • The Second Affiliated Hospital of Xi'an Jiaotong University
        • Contact:
    • Sichuan
      • Chengdu, Sichuan, China, 610000
        • Not yet recruiting
        • Chengdu Second People's Hospital
        • Contact:
      • Chengdu, Sichuan, China, 610000
        • Not yet recruiting
        • Sichuan Provincial People' s Hospital
        • Contact:
      • Luzhou, Sichuan, China, 646000
        • Not yet recruiting
        • The affiliated hospital of Southwest Medical University
        • Contact:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300052
        • Not yet recruiting
        • Tianjin Medical University General Hospital
        • Contact:
      • Tianjin, Tianjin Municipality, China, 300120
        • Not yet recruiting
        • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
        • Contact:
    • Xinjiang
      • Ürümqi, Xinjiang, China, 830001
        • Not yet recruiting
        • People's Hospital of Xinjiang Uygur Autonomous Region
        • Contact:
      • Ürümqi, Xinjiang, China, 830013
        • Not yet recruiting
        • The first affiliated hospital of Xinjiang medical university
        • Contact:
    • Yunnan
      • Kunming, Yunnan, China, 650032
        • Not yet recruiting
        • The First Affiliated Hospital of Kunming Medical University
        • Contact:
    • Zhejiang
      • Jiaxing, Zhejiang, China, 314001
        • Not yet recruiting
        • Jiaxing First Hospital
        • Contact:
      • Ningbo, Zhejiang, China, 315020
        • Not yet recruiting
        • The First Affiliated Hospital of Ningbo University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age ≥ 18 or ≤75 years old at screening, regardless of gender;
  • Meet the diagnostic criteria defined by the 2017 European Society for Clinical Nutrition and Metabolism (ESPEN) Research Workshop (ERASPEN) consensus and be diagnosed as （generalized pustular psoriasis(GPP);
  • Compliant with GPP acute onset;
  • Able to read and understand, and willing to sign the informed consent form;
  • Willing and compliant with study visits and related procedures;
  • Female subjects of childbearing age should agree that contraceptive measures must be used during the study and for 6 months after the end of the study;

Exclusion Criteria:

  • Pustules are limited to psoriasis vulgaris on psoriasis plaques;
  • Concomitant skin disease or medical disease that may interfere with the investigator's evaluation of the subject's treatment response;
  • Presence of severe, progressive, or uncontrolled disease, or signs and symptoms that are not suitable for participation in the investigator, in the judgment of the investigator:
  • Serum virological abnormalities during the screening period;
  • Chest radiology examination shows that the subject has active tuberculosis or a history of contact with open tuberculosis subjects in the past 6 months or a positive Interferon-Gamma Release Assays(IGRA) test;
  • History of serious infection leading to hospitalization within 2 months prior to baseline;
  • Active infection requiring systemic antibiotics, systemic antifungals, or systemic antiviral therapy within 2 weeks prior to baseline, according to the investigator's assessment;
  • History of opportunistic infection within 6 months prior to baseline;
  • Received live (attenuated) vaccine treatment within 12 weeks prior to baseline;
  • Any major surgery within 4 weeks prior to baseline or planned major surgery during the study;
  • Received blood transfusion within 4 weeks prior to baseline;
  • Participated in clinical trials of other drugs or medical devices within 4 weeks before baseline;
  • Any known or suspected congenital or acquired immunodeficiency state or condition that may compromise the subject's immune status;
  • Subjects with any type of active malignancy or a history of malignancy;
  • Alcohol, drug and known drug dependence;
  • Pregnant or lactating women;
  • Subjects cannot tolerate intravenous infusion administration.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TQH2929 Injections
Intravenous infusion, single dose
Drug: TQH2929 Injections
TQH2929 is a humanized monoclonal antibody that interfering with the signal cascade.
Placebo Comparator: TQH2929 Placebo
Intravenous infusion, single dose
Drug: TQH2929 Placebo
Placebo contains no active substance.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of patients with a score of 0 for the pustule subterm
Time Frame: 1 week
Percentage of patients with a Physician's Global Assessment of Generalized Pustular Psoriasis (GPPGA) pustular subitem of 0 (no visible pustules) at week 1 among all enrolled patients.
1 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of patients with a Generalized Pustular Psoriasis Physician Global Assessment(GPPGA) total score of 0 or 1
Time Frame: 1 week and 4 weeks
Percentage of patients with a total Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of 0 (clear) or 1 (almost clear) at weeks 1 and 4.
1 week and 4 weeks
Percentage change from baseline in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) total score
Time Frame: 1 week and 4 weeks
Percentage change from baseline in the total score of generalized pustular psoriasis area and severity index (GPPASI) at week 1 and week 4.
1 week and 4 weeks
Change from baseline in Generalized Pustular Psoriasis Area and Severity Index(GPPASI) total score
Time Frame: 1 week and 4 weeks
Change from baseline in Generalized Pustular Psoriasis Area and Severity Index(GPPAS) total score at week 1 and week 4. If lower than the baseline score, indicate a certain degree of disease relief; conversely, if higher, it indicates an aggravation of the disease symptoms.
1 week and 4 weeks
Percentage of patients with Generalized Pustular Psoriasis Area and Severity Index(GPPASI) 50
Time Frame: 1 week and 4 weeks
Percentage of patients who achieved Generalized Pustular Psoriasis Area and Severity Index(GPPASI) 50 at week 1 and week 4.
1 week and 4 weeks
Percentage of patients with Generalized Pustular Psoriasis Area and Severity Index(GPPASI) 75
Time Frame: 1 week and 4 weeks
Percentage of patients who achieved Generalized Pustular Psoriasis Area and Severity Index(GPPASI) 75 at week 1 and week 4
1 week and 4 weeks
Percentage of patients with pustule subterm achieving a score of 0
Time Frame: 4 weeks
Percentage of patients with Generalized Pustular Psoriasis Physician Global Assessment(GPPGA) pustule subterm achieving a score of 0 (no visible pustules) at week 4.
4 weeks
Change from baseline in Psoriasis Symptom Scale (PSS) score
Time Frame: 4 weeks
Change from baseline in Psoriasis Symptom Scale (PSS) score at week 4
4 weeks
Change from baseline in disease life quality index (DLQI)
Time Frame: 4 weeks
Change from baseline in skin disease life quality index (DLQI) at week 4. If lower than the baseline score, indicate a certain degree of disease relief; conversely, if higher, it indicates an aggravation of the disease symptoms.
4 weeks
Adverse Drug Event (AE)
Time Frame: 113 days or 169 days
Any untoward medical occurrence of a subject following drug treatment or exposure to an experimental factor, whether or not causally related to treatment or exposure.
113 days or 169 days
Serious Adverse Event (SAE)
Time Frame: 113 days or 169 days
An event that occurs in the course of a clinical trial that results in the death of a subject or patient, serious deterioration in health, hospitalization or prolongation of hospitalization, permanent disability or loss of function, or serious consequences such as birth defects or birth defects.
113 days or 169 days
Treatment-Emergent Adverse Events (TEAES)
Time Frame: 113 days or 169 days
Adverse events that occur during treatment, including from the start of treatment to a certain period of time after the end of treatment, may be directly or indirectly related to treatment.
113 days or 169 days
Abnormal clinical laboratory examination indicators
Time Frame: 113 days or 169 days
Any laboratory abnormalities that occur during the test.
113 days or 169 days
Time of maximum concentration (Tmax)
Time Frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
It refers to the time it takes for the human blood concentration curve to reach the highest concentration (peak concentration) after a single dose, measured in hours or minutes.
1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
Maximum Concentration (Cmax)
Time Frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
The highest blood concentration reached after the drug is absorbed in the body.
1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
Area Under the Curve (AUC)
Time Frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
It refers to the area covered by the concentration of a drug in the blood under the curve of changes over time.
1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
Apparent Volume of Distribution(Vd/F)
Time Frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
When the drug reaches dynamic equilibrium in the body, the ratio of the amount of drug in the body to the blood concentration is called the apparent volume of distribution.
1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
Apparent Clearance (CL/F)
Time Frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
The sum of drug clearance rates of liver and kidney, etc.
1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
Plasma half-life time (t1/2)
Time Frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
The time it takes for the concentration of the drug in the plasma to drop by half.
1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
Anti-drug antibody (ADA)
Time Frame: Through study completion, an average of half a year
Incidence of anti-drug antibodies (ADA) in subjects.
Through study completion, an average of half a year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 19, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

July 1, 2027

Study Registration Dates

First Submitted

December 15, 2025

First Submitted That Met QC Criteria

December 31, 2025

First Posted (Actual)

January 2, 2026

Study Record Updates

Last Update Posted (Actual)

March 24, 2026

Last Update Submitted That Met QC Criteria

March 20, 2026

Last Verified

October 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TQH2929-II-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Generalized Pustular Psoriasis

Clinical Trials on TQH2929 Injections

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe